FeedworthyAI
About RSSAI/GEO Feed Optimization
Sign InGet Started
Back to feed
Home | Pharma ManufacturingBusiness & Financenews

Lonza sees flurry of ADC technology licensing agreements

Wednesday, June 24, 2026 (Greg Slabodkin)View original
In the space of three weeks, the company has announced four separate antibody-drug conjugate deals with AmMax Bio, Antharis Therapeutics, InduPro, and Stipple Bio.

Read the full article on the original site.

Read Full Article
Back to feedView original
FeedworthyAI·Privacy Policy·Terms of Service